Cohance Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)
Cohance Lifesciences Ltd · Outcome · 06 Nov 2026, 11:18 pm
Cohance Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 477 (-14.2% YoY | +12.9% QoQ) ■ EBITDA: 35.4 (-70.7% YoY | +2950.0% QoQ) ■ EBITDA Margin (%): 7.4 (-1435 bps YoY | +715 bps QoQ) ■ PAT: 15.2 (-79.5% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.38 (-80.3% YoY | Loss to Profit QoQ)
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... · 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others · 12 Nov 2026
- Investors Meet · 11 Nov 2026
- Transcript of Con call · 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others · 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others · 11 Nov 2026
- Investor Presentation · 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. · 07 Nov 2026
